Cargando…
1433. Impact of 2019 US Food and Drug Administration (FDA) Guidance on Developing Drugs for Urinary Tract Infection (UTI) on the Perceived Efficacy of Antibiotics for the Treatment of Uncomplicated UTI (uUTI)
BACKGROUND: In 2019, the FDA issued guidance on drug development for treatment of UTIs. To explore the impact of this guidance, we compared clinical and microbiological outcomes of the fluoroquinolones norfloxacin and ciprofloxacin and the β-lactams pivmecillinam and sulopenem for treatment of uUTIs...
Autores principales: | Henriksen, Anne Santerre, Nicolle, Lindsay, Das, Anita F |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8644928/ http://dx.doi.org/10.1093/ofid/ofab466.1625 |
Ejemplares similares
-
1428. Increased Consumption of Pivmecillinam in Primary Care for Uncomplicated Urinary Tract Infection (uUTI) Is Not Associated With Increased Resistance Rates
por: Larsen, Anders Rhod, et al.
Publicado: (2021) -
1453. Cephalexin and Cefadroxil Are Not Therapeutic Equivalents for Uncomplicated Cystitis (uUTI): Further Analysis of Cefazolin Surrogate Susceptibility Testing Criteria
por: Jones, Ronald N, et al.
Publicado: (2019) -
LB-1. Efficacy and Safety of Oral Sulopenem Etzadroxil/Probenecid Versus Oral Ciprofloxacin in the Treatment of Uncomplicated Urinary Tract Infections (uUTI) in Adult Women: Results from the SURE-1 Trial
por: Dunne, Michael W, et al.
Publicado: (2020) -
Recurrent Urinary Tract Infections: Unraveling the Complicated Environment of Uncomplicated rUTIs
por: Josephs-Spaulding, Jonathan, et al.
Publicado: (2021) -
UTI myths and misconceptions
Publicado: (2020)